1 |
Vaidya, A. H., Rosenthal, D. I., Lang, W., Crooke, J. J., Benjamin, D., Ilyin, S. E. and Reitz, A. B. 2005. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action. Methods Find Exp Clin Pharmacol 27, 245-255.
DOI
ScienceOn
|
2 |
Scholze, P., Ebert, V. and Sieghart, W. 1996. Affinity of various ligands for GABAA receptors containing alpha 4 beta 3 gamma 2, alpha 4 gamma 2, or alpha 1 beta 3 gamma 2 subunits. Eur J Pharmacol 304, 155-162.
DOI
ScienceOn
|
3 |
Shekhar, A. 1993. GABA receptors in the region of the dorsomedial hypothalamus of rats regulate anxiety in the elevated plus-maze test. I. Behavioral measures. Brain Res 627, 9-16.
DOI
ScienceOn
|
4 |
Takeda, H., Tsuji, M. and Matsumiya, T. 1998. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 350, 21-29.
DOI
ScienceOn
|
5 |
Toumi, M. L., Merzoug, S., Baudin, B. and Tahraoui, A. 2013. Quercetin alleviates predator stress-induced anxiety-like and brain oxidative signs in pregnant rats and immune count disturbance in their offspring. Pharmacol Biochem Behav 107, 1-10.
DOI
ScienceOn
|
6 |
Wittchen, H. U. and Hoyer, J. 2001. Generalized anxiety disorder: nature and course. J Clin Psychiatry 62 Suppl 11, 15-19; discussion 20-11.
|
7 |
Zomkowski, A. D., Hammes, L., Lin, J., Calixto, J. B., Santos, A. R. and Rodrigues, A. L. 2002. Agmatine produces antidepressant- like effects in two models of depression in mice. Neuroreport 13, 387-391.
DOI
ScienceOn
|
8 |
Li, Y. F., Gong, Z. H., Cao, J. B., Wang, H. L., Luo, Z. P. and Li, J. 2003. Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol 469, 81-88.
DOI
ScienceOn
|
9 |
Lister, R. G. 1987. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92, 180-185.
|
10 |
Lydiard, R. B. 2003. The role of GABA in anxiety disorders. J Clin Psychiatry 64 Suppl 3, 21-27.
|
11 |
Olsen, R. W. and Sieghart, W. 2008. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 60, 243-260.
DOI
ScienceOn
|
12 |
Pellow, S. and File, S. E. 1986. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plusmaze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24, 525-529.
DOI
ScienceOn
|
13 |
Korte, S. M. and De Boer, S. F. 2003. A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plus-maze. Eur J Pharmacol 463, 163-175.
DOI
ScienceOn
|
14 |
Korpi, E. R., Grunder, G. and Luddens, H. 2002. Drug interactions at GABA(A) receptors. Prog Neurobiol 67, 113-159.
DOI
ScienceOn
|
15 |
Ressler, K. J. and Nemeroff, C. B. 2001. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectr 6, 663-666,670.
DOI
|
16 |
Sadock, B. J., Kaplan, H. I. and Sadock, V. A. 2007. Kaplan and Sadock's Synopsis of Psychiatry, pp. 1470, 10th, Lippincott Williams & Wilkins. Philadelphia.
|
17 |
Sandford, J. J., Argyropoulos, S. V. and Nutt, D. J. 2000. The psychobiology of anxiolytic drugs. Part 1: Basic neurobiology. Pharmacol Ther 88, 197-212.
DOI
ScienceOn
|
18 |
Bennet, D. and Kim, S. 2013. Impedance-based cell culture platform to assess light-induced stress changes with antagonist drugs using retinal cells. Anal Chem 85, 4902-4911.
DOI
ScienceOn
|
19 |
Bhutada, P., Mundhada, Y., Bansod, K., Ubgade, A., Quazi, M., Umathe, S. and Mundhada, D. 2010. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice. Prog Neuropsy chopharmacol Biol Psychiatry 34, 955-960.
DOI
ScienceOn
|
20 |
Bonetti, E. P., Pieri, L., Cumin, R., Schaffner, R., Pieri, M., Gamzu, E. R., Muller, R. K. and Haefely, W. 1982. Benzodiazepine antagonist Ro 15-1788: neurological and behavioral effects. Psychopharmacology (Berl) 78, 8-18.
DOI
|
21 |
Chebib, M. 2004. GABAC receptor ion channels. Clin Exp Pharmacol Physiol 31, 800-804.
DOI
ScienceOn
|
22 |
Chirumbolo, S. 2012. Quercetin in Cancer Prevention and Therapy. Integr Cancer Ther 12, 97-102.
|
23 |
Association, A. P. 1994. Diagnostic and Statistical Manual of Mental Disorders, pp. 393-444, 4th eds., American Psychiatric Association. Washington, D.C. USA.
|
24 |
Dawson, G. R. and Tricklebank, M. D. 1995. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 16, 33-36.
DOI
ScienceOn
|
25 |
Eckeli, A. L., Dach, F. and Rodrigues, A. L. 2000. Acute treatments with GMP produce antidepressant-like effects in mice. Neuroreport 11, 1839-1843.
DOI
ScienceOn
|
26 |
Fabene, P. F., Mariotti, R., Navarro Mora, G., Chakir, A. and Zancanaro, C. 2008. Forced mild physical training-induced effects on cognitive and locomotory behavior in old mice. J Nutr Health Aging 12, 388-390.
DOI
|
27 |
Flores-Gracia, C., Nuche-Bricaire, A., Crespo-Ramirez, M., Miledi, R., Fuxe, K. and Perez de la Mora, M. 2010. GABA(A) rho receptor mechanisms in the rat amygdala and its role in the modulation of fear and anxiety. Psychopharmacology (Berl) 212, 475-484.
DOI
|
28 |
Moreira, F. A., Aguiar, D. C. and Guimaraes, F. S. 2006. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30, 1466-1471.
DOI
ScienceOn
|
29 |
Bourin, M., Fiocco, A. J. and Clenet, F. 2001. How valuable are animal models in defining antidepressant activity? Human Psychopharmacology 16, 9-21.
DOI
ScienceOn
|